M

Matthias P. Wymann

University of Basel

ORCID: 0000-0003-3349-4281

Publishes on PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Chronic Lymphocytic Leukemia Research. 211 papers and 18.7k citations.

PubIndex Score98Top 2%How it's scored

211Publications

18.7kTotal Citations

First publication: 1987First senior author: 1989

PI3K/AKT/mTOR signaling in cancer Protein Kinase Regulation and GTPase Signaling Chronic Lymphocytic Leukemia Research Mast cells and histamine Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Top publicationsby citations

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, Matthias P. Wymann|Nature Communications|2017

Cited by 115

Human neutrophil migration into skin chambers is associated with ProductionI of NAP‐1/IL8 and C5a

Per Follin, Cláes Dahlgren, M. Ceska et al.|European Journal Of Haematology|1991

Cited by 50

Chemical and Structural Strategies to Selectively Target mTOR Kinase

Chiara Borsari, Matthias P. Wymann|ChemMedChem|2021

Cited by 25

Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling

Lukas Bissegger, Matthias P. Wymann|Chemical Science|2024

Cited by 7

Targeting melanoma with dual phosphoinosite 3-kinase/mammalian target of rapamycin inhibitors

Romina Marone, Matthias P. Wymann|BMC Biology|2009

Cited by 0